PENTASA: clinically demonstrated to improve patients' quality of life (QOL)

PENTASA (4 grams/day) significantly reduced clinical symptom severity, thereby improving the functions of everyday living.11

Mean % symptom reduction and function improvement (*,11)

Adapted from Robinson, et al, 1994.11

*In an 8-week study, patients with distal UC or pancolitis were randomized to receive PENTASA (1, 2, or 4 grams/day) or placebo. QOL parameters were measured using a visual analogue scale, where 0 indicated complete symptom relief and 10 indicated severe symptoms. Patients recorded actual number of trips to toilet in a diary.11

†P<0.02 vs placebo

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.